Literature DB >> 10414159

Cause, treatment and outcome of patients with life-threatening haemoptysis.

A E Stebbings1, T K Lim.   

Abstract

BACKGROUND: Massive haemoptysis is a life-threatening situation which requires immediate medical attention and intervention. We reviewed 23 patients with life-threatening haemoptysis to document the cause, describe the treatment of these patients and to determine which form of treatment had a better outcome.
DESIGN: Retrospective case study.
METHODS: Consecutive patients were reviewed and data collected for the underlying cause, treatment and outcome of patients with life-threatening haemoptysis.
RESULTS: Out of 23 patients, nine patients had active pulmonary tuberculosis and nine patients had post-tuberculous lung disease. Fifteen patients underwent bronchial embolisation, one patient had surgical resection and seven patients had received medical treatment. Five patients required intubation. Bronchial embolisation was significantly better than medical treatment at immediate cessation of haemoptysis (p < 0.05). Three (13%) patients died from haemoptysis. Follow-up duration averaged 16 months.
CONCLUSIONS: The most common causes of haemoptysis were pulmonary tuberculosis and post-tuberculous bronchiectasis. Urgent bronchial artery embolisation was better at immediate cessation of haemoptysis than medical treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10414159

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  3 in total

1.  Lessons from patients with hemoptysis attending a chest clinic in India.

Authors:  Rajendra Prasad; Rajiv Garg; Sanjay Singhal; Piyush Srivastava
Journal:  Ann Thorac Med       Date:  2009-01       Impact factor: 2.219

2.  Hemoptysis, a developing world perspective.

Authors:  Omer Ashraf
Journal:  BMC Pulm Med       Date:  2006-01-13       Impact factor: 3.317

Review 3.  Approach to Hemoptysis in the Modern Era.

Authors:  Sébastien Gagnon; Nicholas Quigley; Hervé Dutau; Antoine Delage; Marc Fortin
Journal:  Can Respir J       Date:  2017-12-21       Impact factor: 2.409

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.